Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Pharmaust Limited ( (AU:NUZ) ) is now available.
Neurizon Therapeutics Limited has informed the market that 682,500 options with an exercise price of $0.10, expiring on 28 February 2026, have lapsed unexercised. The expiry of these options marginally reduces the company’s pool of potential equity overhang, simplifying its capital structure but providing no immediate change to its current cash position or outstanding share count.
The cessation of these securities reflects standard option lifecycle management and may slightly adjust future dilution expectations for existing shareholders. While operational activities remain unaffected, the update offers investors greater clarity on Neurizon’s issued capital and the evolution of its equity-based incentives and financing capacity.
The most recent analyst rating on (AU:NUZ) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited, listed on the ASX under the code NUZ, is a therapeutics company focused on the development of pharmaceutical treatments. The company operates in the biotechnology and healthcare sector, concentrating on innovative drug development to address unmet medical needs in its target markets.
Average Trading Volume: 580,820
Technical Sentiment Signal: Sell
Current Market Cap: A$62.88M
Find detailed analytics on NUZ stock on TipRanks’ Stock Analysis page.